BLPH - ベレロフォン・セラピュ―ティクス （Bellerophon Therapeutics Inc.） ベレロフォン・セラピュ―ティクスBLPHのチャート
BLPHの企業情報
| symbol | BLPH |
|---|---|
| 会社名 | Bellerophon Therapeutics Inc （ベレロフォン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Bellerophon Therapeutics Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system INOpulse with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs which minimizes the amount of drug required for treatment. The Company''s second program BCM is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI) which is a type of severe heart attack. The Company''s BCM is in PRESERVATION I clinical trial. ベレロフォン・セラピュ―ティクスは、米国のバイオ医薬品会社。心肺や心臓疾患の治療における医療ニ―ズに対応する薬と装置を中心に製品開発を行う。最初のプログラムであるINOpulseは、拍動一酸化窒素送達デバイスに基づいて開発され、肺動脈高血圧症の治療のための製品と、慢性閉塞性肺疾患に関連する肺高血圧症の治療用の製品を提供する。 Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. |
| 本社所在地 | 184 Liberty Corner Road Suite 302 Warren NJ 07059 USA |
| 代表者氏名 | Jonathan M. Peacock ジョナサン・M・ピーコック |
| 代表者役職名 | Chairman of the Board President 取締役会長会長 |
| 電話番号 | +1 908-574-4770 |
| 設立年月日 | 41548 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 20人 |
| url | www.bellerophon.com |
| nasdaq_url | https://www.nasdaq.com/symbol/blph |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -29.49600 |
| 終値（lastsale） | 1.23 |
| 時価総額（marketcap） | 71092323.51 |
| 時価総額 | 時価総額（百万ドル） 67.62441 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 41.72541 |
| 当期純利益 | 当期純利益（百万ドル） -39.12000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Bellerophon Therapeutics Inc revenues was not reported. Net loss decreased 68% to $7.4M. Lower net loss reflects Change in fair value of common stock war increase from $12M (expense) to $3.4M (income) Interest and other income increase from $53K to $190K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.72 to -$0.13. |
BLPHのテクニカル分析
BLPHのニュース
Bellerophon Therapeutics to raise $5M in stock and warrants offering 2023/03/06 13:44:37 Seeking Alpha
Bellerophon Therapeutics (BLPH) entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares…
Bellerophon Therapeutics Announces $5 Million Registered Direct Offering 2023/03/06 13:30:00 GlobeNewswire
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock at a price of $2.00 per share and 1,781,526 prefunded warrants at a price of $1.99 per pre-funded warrant for total gross proceeds of approximately $5 million, before deducting estimated offering expenses. The offering is expected to close on March 7, 2023, subject to the satisfaction of customary closing conditions.
Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse in Fibrotic Interstitial Lung Disease | MarketScreener 2023/02/10 14:34:48 MarketScreener
Bellerophon Therapeutics, Inc. , a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Investigational New Drug … | February 10, 2023
Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse in Fibrotic Interstitial Lung Disease 2023/02/09 13:30:00 Wallstreet:Online
China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint WARREN, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Investigational New Drug
Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease 2023/02/09 13:30:00 GlobeNewswire
China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday 2022/09/28 09:10:27 Benzinga
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares climbed 106.3% to close at $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Scienjoy Holding Corporation (NASDAQ: SJ ) climbed 47.9% to close at $2.47 after declining 44% on Monday. Sonendo, Inc. (NASDAQ: SONX ) gained 42.7% to close at $1.67. Sonendo recently announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million led by a consortium of new and existing investors. X4 Pharmaceuticals, Inc. (NASDAQ: XFOR ) gained 40.2% to close at $1.25 after the company announced data from its Phase 1b trial evaluating mavorixafor in chronic neutropenia. Antelope Enterprise Holdings Limited (NASDAQ: AEHL ) rose 37.5% to settle at $0.9320.
Nasdaq Turns Higher; Crude Oil Rises Over 2% 2022/09/27 18:58:07 Benzinga
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.22% to 29,196.13 while the NASDAQ rose 0.31% to 10,836.79. The S&P 500 also fell, dropping, 0.06% to 3,652.89. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 0.7% on Tuesday. In trading on Tuesday, utilities shares dipped by 2%. Top Headline New home sales jumped 28.8% from a month ago to a five-month high of 685,000 in August. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 170% to $9.52. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 27% to $2.7581 as the company issued a corporate update after IPO .
US Stocks Turn Lower; Dow Dips 175 Points 2022/09/27 16:41:11 Benzinga
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday. The Dow traded down 1.60% to 29,085.07 while the NASDAQ fell 0.31% to 10,769.06. The S&P 500 also fell, dropping, 0.50% to 3,636.85. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 1.1% on Tuesday. In trading on Tuesday, utilities shares fell 1.8%. Top Headline The S&P CoreLogic Case-Shiller 20-city home price index rose 16.1% year-over-year in July. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 147% to $8.70. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 38% to $2.9894 as the company issued a corporate update after IPO .
BLPH (NASDAQ:BLPH) Soars on FDA Nod to Lung Study Change; Street Sees 24x Gains 2022/09/27 16:25:01 TipRanks
Shares of clinical-stage company Bellerophon Therapeutics (NASDAQ:BLPH) are soaring high today after the U.S. Food and Drug Administration (FDA) agreed to a reduction in the size of BLPH’s Phase 3 study of INOpulse for treating fibrotic interstitial lung disease (fiLD). The data monitoring committee of the study supported lowering the study size to 140 from 300 and the change does not affect the trial’s principal objective or endpoints. The company expects to complete enrolment in Q1 2023 with top-line data expected in Q3 2023.
Why Are Bellerophon Shares Jumping Today? 2022/09/27 16:07:58 Benzinga
The FDA has accepted Bellerophon Therapeutics Inc''s (NASDAQ: BLPH ) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD). The new study size of 140 subjects does not impact the trial''s … Full story available on Benzinga.com
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday 2022/09/28 09:10:27 Benzinga
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares climbed 106.3% to close at $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Scienjoy Holding Corporation (NASDAQ: SJ ) climbed 47.9% to close at $2.47 after declining 44% on Monday. Sonendo, Inc. (NASDAQ: SONX ) gained 42.7% to close at $1.67. Sonendo recently announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million led by a consortium of new and existing investors. X4 Pharmaceuticals, Inc. (NASDAQ: XFOR ) gained 40.2% to close at $1.25 after the company announced data from its Phase 1b trial evaluating mavorixafor in chronic neutropenia. Antelope Enterprise Holdings Limited (NASDAQ: AEHL ) rose 37.5% to settle at $0.9320.
Nasdaq Turns Higher; Crude Oil Rises Over 2% 2022/09/27 18:58:07 Benzinga
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.22% to 29,196.13 while the NASDAQ rose 0.31% to 10,836.79. The S&P 500 also fell, dropping, 0.06% to 3,652.89. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 0.7% on Tuesday. In trading on Tuesday, utilities shares dipped by 2%. Top Headline New home sales jumped 28.8% from a month ago to a five-month high of 685,000 in August. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 170% to $9.52. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 27% to $2.7581 as the company issued a corporate update after IPO .
US Stocks Turn Lower; Dow Dips 175 Points 2022/09/27 16:41:11 Benzinga
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday. The Dow traded down 1.60% to 29,085.07 while the NASDAQ fell 0.31% to 10,769.06. The S&P 500 also fell, dropping, 0.50% to 3,636.85. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 1.1% on Tuesday. In trading on Tuesday, utilities shares fell 1.8%. Top Headline The S&P CoreLogic Case-Shiller 20-city home price index rose 16.1% year-over-year in July. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 147% to $8.70. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 38% to $2.9894 as the company issued a corporate update after IPO .
BLPH (NASDAQ:BLPH) Soars on FDA Nod to Lung Study Change; Street Sees 24x Gains 2022/09/27 16:25:01 TipRanks
Shares of clinical-stage company Bellerophon Therapeutics (NASDAQ:BLPH) are soaring high today after the U.S. Food and Drug Administration (FDA) agreed to a reduction in the size of BLPH’s Phase 3 study of INOpulse for treating fibrotic interstitial lung disease (fiLD). The data monitoring committee of the study supported lowering the study size to 140 from 300 and the change does not affect the trial’s principal objective or endpoints. The company expects to complete enrolment in Q1 2023 with top-line data expected in Q3 2023.
Why Are Bellerophon Shares Jumping Today? 2022/09/27 16:07:58 Benzinga
The FDA has accepted Bellerophon Therapeutics Inc''s (NASDAQ: BLPH ) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD). The new study size of 140 subjects does not impact the trial''s … Full story available on Benzinga.com